Heterocyclic Compounds

Matches 701 - 750 out of 36,905	< 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 >

Document	Document Title
WO/2023/173016A1	KRAS INHIBITORS FOR TREATING DISEASE The present disclosure relates to diaryl compounds targeting KRAS, pharmaceutical compositions containing the compounds, and methods of using such compounds to treat disease, such as cancer.
WO/2023/169436A1	BENZO BICYCLIC COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF Disclosed in the present invention are a benzo bicyclic compound, and a preparation method and application thereof. Specifically disclosed is a compound, which is a compound as shown in formula (X), or a stereoisomer, geometric isomer, t...
WO/2023/169438A1	NITROGEN-CONTAINING HETEROCYCLIC CELL CYCLE INHIBITOR COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF The invention relates to nitrogen-containing heterocyclic compounds as well as a preparation method therefor and the use thereof, in particular to a nitrogen-containing heterocyclic compound represented in general formula (I), or a pharm...
WO/2023/169547A1	DNA POLYMERASE θ INHIBITOR AND USE THEREOF A nitrogen-containing heterocyclic compound represented by formula (I-c), or a stereoisomer, a deuterated compound or a pharmaceutically acceptable salt, and a pharmaceutical composition thereof. Also provided is a use of the compound in...
WO/2023/165504A1	DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF Described herein are DGKalpha inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with DGKalpha.
WO/2023/165509A1	DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF Described herein are DGKalpha inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with DGKalpha.
WO/2023/168378A1	PI3KA INHIBITORS The present disclosure provides compounds, compositions, and methods useful for inhibiting PI3Ka, and/or treating a disease, disorder, or condition associated with PI3Ka, and/or treating cancer. (Formula I)
WO/2023/167279A1	METHOD FOR CONTROLLING HARMFUL ARTHROPODS OR HARMFUL NEMATODES USING ZOANTHAMINE ANALOG The present invention provides a method for controlling harmful arthropods or harmful nematodes. Compounds represented by formula (I) [in the formula, R1 represents a hydrogen atom, etc., R2 represents ORA2, R3, R7, R14, R17, R19, and R2...
WO/2023/166450A1	NOVEL HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME The present invention relates to a compound represented by chemical formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof, and a pharmaceutical composition comprising same.
WO/2023/165079A1	DIPYRIDINOPHENAZINE THERMALLY ACTIVATED DELAYED FLUORESCENT MATERIAL DOPED WHITE ELECTROLUMINESCENT DEVICE The present invention relates to a dipyridinophenazine thermally activated delayed fluorescent material doped white electroluminescent device, which is obtained by sequentially carrying out vacuum evaporation on a hole injection layer, a...
WO/2023/167475A1	IMPROVED PREPARATION METHOD FOR RUCAPARIB The present invention relates to an improved preparation method for rucaparib, enabling excellent synthesis yield and reproducibility to be achieved. More particularly, the present invention relates to: an improved preparation method for...
WO/2023/165525A1	DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF Provided are DGKalpha inhibitors and pharmaceutical compositions comprising said inhibitors. The compounds and compositions are useful for the treatment of a disease or disorder associated with DGKalpha.
WO/2023/165493A1	NAPHTHYRIDINE DERIVATIVE AND USE THEREOF Disclosed are a naphthyridine derivative and use thereof. The naphthyridine derivative can well inhibit ATR kinase activity and can be used in the preparation of an ATR kinase inhibitor, particularly in the preparation of a medicament ag...
WO/2023/165077A1	THERMALLY ACTIVATED DELAYED FLUORESCENT MATERIAL BASED ON DIPYRIDINOPHENAZINE ACCEPTOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to a thermally activated delayed fluorescent material based on a dipyridino[3,2-a:2',3'-c]phenazine acceptor and a preparation method therefor. The thermally activated delayed fluorescent material is 11-(9,9...
WO/2023/167234A1	COMPOUND, ORGANIC THIN FILM, PHOTOELECTRIC CONVERSION ELEMENT, IMAGING ELEMENT, PHOTOSENSOR AND SOLID-STATE IMAGING DEVICE The present invention provides a compound which is represented by formula (1) (wherein each of R1 to R6 independently represents a hydrogen atom, a halogen atom, a linear, branched or cyclic alkyl group, or the like).
WO/2023/165570A1	CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF The present invention relates to a compound of formula (I) or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutical composition thereof, and a use of the compound...
WO/2023/165501A1	CRYSTAL FORM OF AZD5305, PREPARATION METHOD THEREFOR, AND USE THEREFOR The present application relates to the field of chemical synthesis of pharmaceutics. Specifically, the present application relates to a crystal form of AZD5305, a preparation method therefor, and use thereof. The crystal form provided by...
WO/2023/165438A1	TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF The present invention relates to a substituted tricyclic derivative, a preparation method therefor, and pharmaceutical use of a pharmaceutical composition comprising same. Specifically, the present invention relates to a substituted tric...
WO/2023/165574A1	COMPOUND USED AS TYK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF Disclosed are a compound used as a TYK2 inhibitor, a preparation method therefor, and pharmaceutical use thereof. Specifically, the compound has a structure represented by formula (I), wherein the definitions of the groups and substituen...
WO/2023/165078A1	RED-LIGHT ELECTROLUMINESCENT DEVICE BASED ON BIPYRIDINE PHENAZINE THERMALLY ACTIVATED DELAYED FLUORESCENT MATERIAL The present invention relates to a red-light electroluminescent device based on a bipyridine phenazine thermally activated delayed fluorescent material. A hole injection layer, a hole transport layer, a barrier layer, a light-emitting la...
WO/2023/165581A1	PYRIDINE DERIVATIVE AND USE THEREOF Disclosed are a pyridine derivative represented by formula I and use thereof. The compound has a significant inhibitory effect on KRAS and PI3K protein activities and can be used as a KRAS and/or PI3K protein inhibitor and in preparing a...
WO/2023/160652A1	SUBSTITUTED FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USES THEREOF Provided are a substituted fused ring compound represented by formula (I), a pharmaceutical composition thereof, a preparation method therefor and the uses thereof. The compound has a good LRRK2 kinase regulation/inhibition effect, and t...
WO/2023/164237A1	COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein. These compounds are useful in methods for stabilizing a mutant PAH protein or reducing bloo...
WO/2023/160527A1	PYRIMIDO AROMATIC RING COMPOUND AND USE THEREOF IN DRUG A pyrimido aromatic ring compound and a use thereof in a drug, especially a use thereof as a TLR8 agonist. Specifically, the present invention relates to a compound represented by general formula (I), or a stereoisomer, tautomer, nitroge...
WO/2023/164358A1	GLP-1R MODULATING COMPOUNDS The present application describes GLP-IR modulating compounds that are useful for treating GLP-IR-mediated diseases or conditions.
WO/2023/163140A1	INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF The purpose of the present invention is to provide a compound that exhibits an H-PGDS inhibitory activity. The present invention relates to a compound expressed by formula [I] or a pharmaceutically acceptable salt thereof (in the formula...
WO/2023/164680A1	6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6, such as e.g. cancer and inflammatory conditi...
WO/2023/164233A1	(4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein. These compounds are useful in methods for stabilizing a mutant PAH protein or reducing bloo...
WO/2023/164063A1	EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.
WO/2023/160577A1	FUSED BICYCLIC COMPOUND CONTAINING PYRROLINONE The present application relates to the field of pharmaceutical chemistry, relates to a fused bicyclic compound containing pyrrolinone, and in particular relates to a compound represented by formula (II), a stereoisomer or a pharmaceutica...
WO/2023/163479A1	ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME The present invention relates to a novel compound with excellent carrier transport ability, light-emitting ability, and thermal stability, and an organic electroluminescent device that includes the compound in at least one organic materi...
WO/2023/161316A1	ZWITTERIONIC ANTIBACTERIAL COMPOUNDS The invention provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein A, X, R1-R9, R12 and R13 are as described herein (I). Further provided are pharmaceutical ...
WO/2023/164612A1	MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN Disclosed herein are compounds (I) and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of d...
WO/2023/161317A1	5-[7-(3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBONYL)-1,2,3,4 TETRAHYDROISOQUINOLIN-6-Y L]-1H-PYRROLE-3-CARBOXAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS A compound of formula (I): (I) wherein R3, R4, R5, R6, Z1, Z2 and T are as defined in the description. Medicaments.
WO/2023/160552A1	SPIRO-COMPOUND AND USE THEREOF Disclosed in the present invention are a spiro-compound and the use thereof, and in particular, disclosed are a compound as shown in a formula (III), and a stereoisomer or a pharmaceutically acceptable salt thereof.
WO/2023/164236A1	COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein. These compounds are useful in methods for stabilizing a mutant PAH protein or reducing bloo...
WO/2023/163553A1	MITOCHONDRIA-TARGETING CANCER THERAPEUTIC COMPOSITION The present invention relates to a compound bearing a photosensitizer and an imidazopyridine derivative, a liposome including the compound, and a photodynamic therapeutic composition containing the compound or liposome. According to exem...
WO/2023/160572A1	PYRAZOLE DERIVATIVE, PHARMACEUTICAL COMPOSITION, AND USE Disclosed are a pyrazole derivative, a pharmaceutical composition, and use. The pyrazole derivative has a structure represented by formula (I). The pyrazole derivative has a good selectivity for inhibiting the activity of CDK2.
WO/2023/160187A1	CARBAZOLE DERIVATIVE AND USE THEREOF A derivative of a naphthyl carbazole or naphthyl carboline structure, the use thereof respectively as a luminescent material layer, a hole transport layer, a hole barrier layer or an encapsulation layer material in an organic electrolumi...
WO/2023/164025A1	REGENERATION OF SYMMETRICAL NONAQUEOUS ORGANIC REDOX FLOW BATTERIES A method of regenerating a symmetrical redox flow battery includes: a first discharge process having a duration in which a capacity of the redox flow battery in a first polarity and comprising a membrane decreases from a first to a secon...
WO/2023/155866A1	PYRAZOLOPYRIDINE DERIVATIVE AND APPLICATION THEREOF IN MEDICINE The present invention relates to the compound shown in general formula (I) or to a stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically-acceptable salt or eutectic crystal thereof, and to an interm...
WO/2023/155841A1	SALT FORM AND CRYSTALLINE FORM OF PYRIMIDINE FUSED-RING COMPOUND A salt form and a crystalline form of a pyrimidine fused-ring compound and a preparation method therefor. Specifically, use of a salt form and a crystalline form of the compound of formula (II) in the preparation of treatment-related med...
WO/2023/155892A1	MEMBRANE-ASSOCIATED TYROSINE-AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF Described herein are PKMYT1 (Myt1) inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with PKMYT1.
WO/2023/155710A1	IKZF2 DEGRADATION AGENT, PHARMACEUTICAL COMPOSITION COMPRISING SAME AND USE THEREOF The present invention belongs to the field of medicinal chemistry, and relates to an IKZF2 degradation agent, a pharmaceutical composition comprising same and use thereof. Specifically, the IKZF2 degradation agent has a structure represe...
WO/2023/159155A1	INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) AND USES THEREOF Disclosed herein are compounds of Formulae 1A, 1B, 1C and 1D, (1A), (1B), (1C) and (1D) and methods of making and methods of using the same.
WO/2023/159154A1	SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 Disclosed are compounds of Formulas (I): (Formulas (I)) or a salt thereof, wherein X, Y, Q, G, R1, and R5a are defined herein. Also disclosed are methods of using such compounds as inhibitors of TLR9, and pharmaceutical compositions comp...
WO/2023/157891A1	COMPOSITION FOR USE IN TREATMENT OF CANCER, INFLAMMATORY DISEASES, OR OBESITY, AND USE THEREOF The present invention addresses the problem of providing a drug for use in the treatment of triple-negative breast cancer, providing a blood marker for triple-negative breast cancer, and providing a drug for use in the treatment of infla...
WO/2023/158862A2	STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF The invention provides novel modulators of STING (Stimulator of Interferon Genes) and pharmaceutical compositions thereof, as well as methods of their preparation and use, in therapy of various diseases and conditions, such as cancer, in...
WO/2023/157862A1	METHOD FOR PRODUCING FLUOROETHER Provided is a method for producing α-fluoroether starting from an inactivated chloride. Disclosed is a method for producing a compound represented by formula (3), the method comprising step A in which a compound represented by formula (...
WO/2023/159153A1	SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 Disclosed are compounds of Formulas (I) or a salt thereof, wherein Q, G, R1, R5a, and R5b are defined herein. Also disclosed are methods of using such compounds as inhibitors of TLR9, and pharmaceutical compositions comprising such compo...

Matches 701 - 750 out of 36,905	< 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 >